Scholarlink

<p>Curated electronic health records offer valuable insights into real-world outcomes for patients with advanced tumors. We described real-world treatment effectiveness among patients with HR+/HER2- metastatic breast cancer (mBC) and metastatic triple-negative breast cancer (mTNBC) using ConcertAI Patient360™ Breast Cancer dataset. Patients initiating therapies selected based on literature review and data availability in the metastatic setting between January 1, 2016, and November 30, 2021, were included. Real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time-to-next treatment (rwTTNT), and time-to-discontinuation (rwTTD) were assessed. Three HR+/HER2- mBC cohorts included 292 patients treated with palbociclib + fulvestrant, 274 patients treated with fulvestrant monotherapy, and 381 patients treated with paclitaxel-based therapy; the mTNBC cohort included 247 chemotherapy-treated patients. Median rwOS in three HR+/HER2- cohorts ranged from 15.6 to 32.3&#xa0;months and was 13&#xa0;months in mTNBC; median rwPFS ranged from 5.6 to 8.6&#xa0;months, and 4.4&#xa0;months, respectively. The alignment between several real-world and clinical trial endpoints is encouraging and supports the utility of real-world data in contextualizing outcomes, though interpretation may be influenced by data completeness and variability in clinical documentation. These insights are particularly relevant for populations with persistent unmet clinical needs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Natalia Sadetsky,
  • Patricia Prince,
  • Helen Latimer,
  • Pooja Advani,
  • Demetria Smith-Gaziani,
  • Peter A. Kaufman,
  • Yanina Natanzon,
  • Aliki Taylor,
  • Linda Nguyen,
  • Nick Freemantle

摘要

Curated electronic health records offer valuable insights into real-world outcomes for patients with advanced tumors. We described real-world treatment effectiveness among patients with HR+/HER2- metastatic breast cancer (mBC) and metastatic triple-negative breast cancer (mTNBC) using ConcertAI Patient360™ Breast Cancer dataset. Patients initiating therapies selected based on literature review and data availability in the metastatic setting between January 1, 2016, and November 30, 2021, were included. Real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time-to-next treatment (rwTTNT), and time-to-discontinuation (rwTTD) were assessed. Three HR+/HER2- mBC cohorts included 292 patients treated with palbociclib + fulvestrant, 274 patients treated with fulvestrant monotherapy, and 381 patients treated with paclitaxel-based therapy; the mTNBC cohort included 247 chemotherapy-treated patients. Median rwOS in three HR+/HER2- cohorts ranged from 15.6 to 32.3 months and was 13 months in mTNBC; median rwPFS ranged from 5.6 to 8.6 months, and 4.4 months, respectively. The alignment between several real-world and clinical trial endpoints is encouraging and supports the utility of real-world data in contextualizing outcomes, though interpretation may be influenced by data completeness and variability in clinical documentation. These insights are particularly relevant for populations with persistent unmet clinical needs.